DE602004014965D1 - Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen - Google Patents

Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen

Info

Publication number
DE602004014965D1
DE602004014965D1 DE602004014965T DE602004014965T DE602004014965D1 DE 602004014965 D1 DE602004014965 D1 DE 602004014965D1 DE 602004014965 T DE602004014965 T DE 602004014965T DE 602004014965 T DE602004014965 T DE 602004014965T DE 602004014965 D1 DE602004014965 D1 DE 602004014965D1
Authority
DE
Germany
Prior art keywords
cancer
sup
sub
administering
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004014965T
Other languages
English (en)
Inventor
Jeremy Richard Graff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602004014965D1 publication Critical patent/DE602004014965D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
DE602004014965T 2003-10-24 2004-10-08 Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen Active DE602004014965D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51429103P 2003-10-24 2003-10-24
PCT/US2004/030910 WO2005041953A1 (en) 2003-10-24 2004-10-08 Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases

Publications (1)

Publication Number Publication Date
DE602004014965D1 true DE602004014965D1 (de) 2008-08-21

Family

ID=34549326

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004014965T Active DE602004014965D1 (de) 2003-10-24 2004-10-08 Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen

Country Status (6)

Country Link
US (1) US20060281787A1 (de)
EP (1) EP1684747B1 (de)
AT (1) ATE400268T1 (de)
DE (1) DE602004014965D1 (de)
ES (1) ES2307059T3 (de)
WO (1) WO2005041953A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2009154697A2 (en) * 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
EP2552428A1 (de) 2010-03-30 2013-02-06 Novartis AG Pkc-hemmer zur behandlung von b-zell-lymphom mit chronischer aktiver b-zell-rezeptorsignalisierung
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT817627E (pt) * 1993-12-23 2005-07-29 Lilly Co Eli Inibidores da proteina cinase c
WO2001030331A2 (en) * 1999-10-22 2001-05-03 Eli Lilly And Company Therapeutic compositions including protein kinase c inhibitors
AU2001271261A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor

Also Published As

Publication number Publication date
WO2005041953A1 (en) 2005-05-12
ATE400268T1 (de) 2008-07-15
EP1684747B1 (de) 2008-07-09
ES2307059T3 (es) 2008-11-16
US20060281787A1 (en) 2006-12-14
EP1684747A1 (de) 2006-08-02

Similar Documents

Publication Publication Date Title
EA200200976A1 (ru) Способ лечения или ингибирования полипов ободочной кишки
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
NO20032829D0 (no) Kjemiske forbindelser
DK1353672T3 (da) Syntese af 4-amino-thalidomidenantiomerer
GT199900019A (es) Formulas farmaceuticamente estables de solucion de oxaliplatino.
NO20083207L (no) Inhibitorer av IAP
UY27431A1 (es) Compuestos químicos
UY27435A1 (es) Compuestos químicos
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
IS6658A (is) Ný efnasambönd
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
DE60045508D1 (de) Dalda-analoge und ihre verwendung
Singh Structural optimization of indole based compounds for highly promising anti-cancer activities: Structure activity relationship studies and identification of lead molecules
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
DE602004014965D1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
DE60231426D1 (de) Solubilisierte topoisomerase-gift-mittel
ATE390923T1 (de) Topoisomerase-giftmittel
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
ATE439130T1 (de) Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
ATE381930T1 (de) Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
DE602005015203D1 (de) Neue piperidinsubstituierte diaminothiazole
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336